Source: International Congress 2014 – ILDs 5
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Fähndrich, P. Lepper, S. Henschke, R. Bals, H. Wilkens (Homburg/Saar, Germany). Successful treatment of alveolar proteinosis by inhaled GM-CSF and intravenous rituximab. Eur Respir J 2014; 44: Suppl. 58, 3771

Member's Comments

No comment yet.

Related content which might interest you: Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis Source: International Congress 2014 – ILDs 5 Year: 2014 Clinical features of four children with pulmonary alveolar proteinosis Source: International Congress 2014 – ILDs 5 Year: 2014 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP) Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014